Phoenix is used by 6,000 researchers at 1,500 biopharmaceutical companies and academic institutions in 60 countries.
We are proud to launch Phoenix 8.1, which offers significant statistical, graphical and validation enhancements to automate processes, saving both time and resources, said Thomas Kerbusch, PhD, President of Certara Strategic Consulting.
#Phoenix software winnonlin trainng full
To that end, we are committed to providing a full range of modeling and simulation technology, advisory services, compliance support, and training programs to ensure that scientists optimize their work. ∼ertaras mission is to improve decision-making throughout the drug development continuum we are involved at every step from selecting the best drug candidate to demonstrating its value to payers and health authorities. 90% of novel drugs approved by the US FDA are from companies that leverage Phoenix in their R&D programs. Phoenix is the most advanced and widely-used validated software for pharmacokinetic (PK), pharmacodynamic (PD), and toxicokinetic (TK) modeling and simulation worldwide. PRINCETON, NJ - Certara®, the global leader in model-informed drug development, regulatory science, market access and real-world evidence services, today announced the launch of Phoenix® 8.1. Certara provides scientists with automated, comprehensive tools for PK/PD analysis and modeling, and announces industry's first PK/PD certification program for Phoenix software in partnership with Credly